{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:56:08Z","timestamp":1782316568876,"version":"3.54.5"},"reference-count":64,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,14]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic nonresolving inflammatory syndrome is a major disease feature in myeloproliferative neoplasms (MPNs). Systemic inflammation promotes the growth of the JAK2-V617F+ hematopoietic stem cell clone and is associated with constitutive symptoms (eg, fever, cachexia, and fatigue). Therefore, it is being discussed whether anti-inflammatory therapy, in addition to the well-established JAK inhibitor therapy, may be beneficial in the control of constitutive symptoms. Moreover, effective control of the inflammatory microenvironment may contribute to prevent transformation into secondary myelofibrosis and acute leukemia. Given the pivotal role of tumor necrosis factor \u03b1 (TNF-\u03b1) in MPN and the distinct roles of TNF-\u03b1 receptor 1 (TNFR1) and TNFR2 in inflammation, we investigated the therapeutic effects of \u03b1TNFR1 and \u03b1TNFR2 antibody treatment in MPN-like disease using the JAK2+\/VF knock-in mouse model. Peripheral blood counts, bone marrow\/spleen histopathology, and inflammatory cytokine levels in serum were investigated. \u03b1TNFR2 antibody treatment decreased white blood cells and modulated the serum levels of several cytokines [CXCL2, CXCL5, interleukin-12(p40)], as well as of macrophage colony-stimulating factor, but they lacked efficacy to ameliorate hematocrit and splenomegaly. \u03b1TNFR1 antibody treatment resulted in the mild suppression of elevated hematocrit of \u221210.7% and attenuated splenomegaly (22% reduction in spleen weight). In conclusion, our studies show that TNFR1 and TNFR2 play different roles in the biology of JAK2-V617F\u2013induced disease that may be of relevance in future therapeutic settings.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004438","type":"journal-article","created":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T09:07:17Z","timestamp":1633079237000},"page":"5349-5359","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Anti-inflammatory treatment in MPN: targeting TNFR1 and TNFR2 in JAK2-V617F\u2013induced disease"],"prefix":"10.1182","volume":"5","author":[{"given":"Peter","family":"M\u00fcller","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology and"},{"name":"Health Campus Immunology, Infectiology, and Inflammation, Medical Center, Otto-von-Guericke University, Magdeburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9653-8715","authenticated-orcid":false,"given":"Conny K.","family":"Baldauf","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology and"},{"name":"Health Campus Immunology, Infectiology, and Inflammation, Medical Center, Otto-von-Guericke University, Magdeburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias R.","family":"Haage","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology and"},{"name":"Health Campus Immunology, Infectiology, and Inflammation, Medical Center, Otto-von-Guericke University, Magdeburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Waldleben","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology and"},{"name":"Health Campus Immunology, Infectiology, and Inflammation, Medical Center, Otto-von-Guericke University, Magdeburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Richter","sequence":"additional","affiliation":[{"name":"Immatics Biotechnologies, Tuebingen, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Pfizenmaier","sequence":"additional","affiliation":[{"name":"Institute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Fischer","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology and"},{"name":"Health Campus Immunology, Infectiology, and Inflammation, Medical Center, Otto-von-Guericke University, Magdeburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,12,9]]},"reference":[{"issue":"4","key":"2021120916264038100_B1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood."},{"issue":"1","key":"2021120916264038100_B2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ajh.24221","article-title":"Myeloproliferative neoplasms: a decade of discoveries and treatment advances","volume":"91","author":"Tefferi","year":"2016","journal-title":"Am J Hematol."},{"issue":"8","key":"2021120916264038100_B3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.exphem.2015.06.007","article-title":"Pathogenesis of myeloproliferative neoplasms","volume":"43","author":"Skoda","year":"2015","journal-title":"Exp Hematol."},{"issue":"25","key":"2021120916264038100_B4","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med."},{"issue":"7","key":"2021120916264038100_B5","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med."},{"issue":"17","key":"2021120916264038100_B6","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med."},{"issue":"4","key":"2021120916264038100_B7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell."},{"issue":"7037","key":"2021120916264038100_B8","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature."},{"issue":"3","key":"2021120916264038100_B9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11899-019-00508-w","article-title":"Key role of inflammation in myeloproliferative neoplasms: instigator of disease initiation, progression, and symptoms","volume":"14","author":"Mendez Luque","year":"2019","journal-title":"Curr Hematol Malig Rep."},{"issue":"10","key":"2021120916264038100_B10","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol."},{"issue":"24","key":"2021120916264038100_B11","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","article-title":"TNF\u03b1 facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms","volume":"118","author":"Fleischman","year":"2011","journal-title":"Blood."},{"issue":"5","key":"2021120916264038100_B12","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00432-017-2354-1","article-title":"Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN","volume":"143","author":"Schn\u00f6der","year":"2017","journal-title":"J Cancer Res Clin Oncol."},{"issue":"5","key":"2021120916264038100_B13","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.exphem.2014.01.006","article-title":"Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications","volume":"42","author":"Pourcelot","year":"2014","journal-title":"Exp Hematol."},{"issue":"11","key":"2021120916264038100_B14","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/ajh.23295","article-title":"Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis","volume":"87","author":"Vaidya","year":"2012","journal-title":"Am J Hematol."},{"issue":"4","key":"2021120916264038100_B15","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1006\/cyto.2002.1994","article-title":"Abnormal production of interleukin (IL)-11 and IL-8 in polycythaemia vera","volume":"20","author":"Hermouet","year":"2002","journal-title":"Cytokine."},{"issue":"9","key":"2021120916264038100_B16","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.3390\/cells9092136","article-title":"Cytokine profiling in myeloproliferative neoplasms: overview on phenotype correlation, outcome prediction, and role of genetic variants","volume":"9","author":"Masselli","year":"2020","journal-title":"Cells."},{"key":"2021120916264038100_B17","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.3389\/fimmu.2020.02093","article-title":"Remodeling the bone marrow microenvironment \u2013 a proposal for targeting pro-inflammatory contributors in MPN","volume":"11","author":"Jutzi","year":"2020","journal-title":"Front Immunol."},{"issue":"28","key":"2021120916264038100_B18","doi-asserted-by":"crossref","first-page":"43974","DOI":"10.18632\/oncotarget.9949","article-title":"Crucial factors of the inflammatory microenvironment (IL-1\u03b2\/TNF-\u03b1\/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in\u00a0vitro study","volume":"7","author":"Sollazzo","year":"2016","journal-title":"Oncotarget."},{"issue":"8","key":"2021120916264038100_B19","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1038\/s41375-019-0379-y","article-title":"Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NF\u03baB signaling","volume":"33","author":"Fisher","year":"2019","journal-title":"Leukemia."},{"issue":"3","key":"2021120916264038100_B20","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","article-title":"JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response","volume":"5","author":"Kleppe","year":"2015","journal-title":"Cancer Discov."},{"issue":"4","key":"2021120916264038100_B21","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1538-7836.2004.00689.x","article-title":"Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study","volume":"2","author":"Reitsma","year":"2004","journal-title":"J Thromb Haemost."},{"issue":"22","key":"2021120916264038100_B22","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative neoplasms","volume":"376","author":"Spivak","year":"2017","journal-title":"N Engl J Med."},{"issue":"12","key":"2021120916264038100_B23","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med."},{"issue":"4","key":"2021120916264038100_B24","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11899-019-00527-7","article-title":"The rationale for immunotherapy in myeloproliferative neoplasms","volume":"14","author":"Masarova","year":"2019","journal-title":"Curr Hematol Malig Rep."},{"issue":"5","key":"2021120916264038100_B25","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/leu.2016.12","article-title":"Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both","volume":"30","author":"Koschmieder","year":"2016","journal-title":"Leukemia."},{"key":"2021120916264038100_B26","doi-asserted-by":"crossref","first-page":"100711","DOI":"10.1016\/j.blre.2020.100711","article-title":"Role of inflammation in the biology of myeloproliferative neoplasms","volume":"42","author":"Koschmieder","year":"2020","journal-title":"Blood Rev."},{"key":"2021120916264038100_B27","doi-asserted-by":"crossref","first-page":"102476","DOI":"10.1155\/2015\/102476","article-title":"MPNs as inflammatory diseases: the evidence, consequences, and perspectives","volume":"2015","author":"Hasselbalch","year":"2015","journal-title":"Mediators Inflamm."},{"issue":"8","key":"2021120916264038100_B28","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41375-019-0487-8","article-title":"Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study","volume":"33","author":"Barbui","year":"2019","journal-title":"Leukemia."},{"issue":"3","key":"2021120916264038100_B29","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ajh.25700","article-title":"Second cancers in MPN: survival analysis from an international study","volume":"95","author":"Marchetti","year":"2020","journal-title":"Am J Hematol."},{"issue":"6","key":"2021120916264038100_B30","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1182\/blood.V99.6.2252","article-title":"Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study","volume":"99","author":"Steensma","year":"2002","journal-title":"Blood."},{"issue":"11","key":"2021120916264038100_B31","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1038\/s41375-018-0131-z","article-title":"Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion","volume":"32","author":"Heaton","year":"2018","journal-title":"Leukemia."},{"issue":"6618","key":"2021120916264038100_B32","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/385729a0","article-title":"A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells","volume":"385","author":"Black","year":"1997","journal-title":"Nature."},{"issue":"6","key":"2021120916264038100_B33","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/JLB.2MR0120-510R","article-title":"Distinct modes of TNF signaling through its two receptors in health and disease","volume":"107","author":"Atretkhany","year":"2020","journal-title":"J Leukoc Biol."},{"issue":"1","key":"2021120916264038100_B34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","article-title":"TNF biology, pathogenic mechanisms and emerging therapeutic strategies","volume":"12","author":"Kalliolias","year":"2016","journal-title":"Nat Rev Rheumatol."},{"issue":"6","key":"2021120916264038100_B35","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrd3030","article-title":"TNF receptor 2 pathway: drug target for autoimmune diseases","volume":"9","author":"Faustman","year":"2010","journal-title":"Nat Rev Drug Discov."},{"key":"2021120916264038100_B36","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3389\/fimmu.2017.01951","article-title":"Expression of tumor necrosis factor receptor 2 characterizes TLR9-driven formation of interleukin-10-producing B cells","volume":"8","author":"Ticha","year":"2018","journal-title":"Front Immunol."},{"key":"2021120916264038100_B37","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3389\/fcell.2020.00401","article-title":"Selective targeting of TNF receptors as a novel therapeutic approach","volume":"8","author":"Fischer","year":"2020","journal-title":"Front Cell Dev Biol."},{"issue":"1","key":"2021120916264038100_B38","doi-asserted-by":"crossref","first-page":"13628","DOI":"10.1038\/s41598-018-31957-7","article-title":"Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis","volume":"8","author":"Williams","year":"2018","journal-title":"Sci Rep."},{"issue":"4","key":"2021120916264038100_B39","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/cbin.10735","article-title":"TNFR1 and TNFR2 differentially mediate TNF-\u03b1-induced inflammatory responses in rheumatoid arthritis fibroblast-like synoviocytes","volume":"41","author":"Zhang","year":"2017","journal-title":"Cell Biol Int."},{"issue":"10","key":"2021120916264038100_B40","doi-asserted-by":"crossref","first-page":"e0163314","DOI":"10.1371\/journal.pone.0163314","article-title":"Selective blocking of TNF receptor 1 attenuates peritoneal dialysis fluid induced inflammation of the peritoneum in mice","volume":"11","author":"K\u00e4lble","year":"2016","journal-title":"PLoS One."},{"issue":"511","key":"2021120916264038100_B41","doi-asserted-by":"crossref","first-page":"eaan0790","DOI":"10.1126\/scisignal.aan0790","article-title":"Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer","volume":"11","author":"Nie","year":"2018","journal-title":"Sci Signal."},{"issue":"10","key":"2021120916264038100_B42","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/s41419-019-1938-x","article-title":"TNFR2 induced priming of the inflammasome leads to a RIPK1-dependent cell death in the absence of XIAP","volume":"10","author":"Knop","year":"2019","journal-title":"Cell Death Dis."},{"issue":"6","key":"2021120916264038100_B43","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells","volume":"17","author":"Mullally","year":"2010","journal-title":"Cancer Cell."},{"issue":"4","key":"2021120916264038100_B44","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/gene.10161","article-title":"VavCre transgenic mice: a tool for mutagenesis in hematopoietic and endothelial lineages","volume":"34","author":"Georgiades","year":"2002","journal-title":"Genesis"},{"issue":"43","key":"2021120916264038100_B45","doi-asserted-by":"crossref","first-page":"12304","DOI":"10.1073\/pnas.1605195113","article-title":"Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration","volume":"113","author":"Dong","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"issue":"4","key":"2021120916264038100_B46","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1084\/jem.172.4.1019","article-title":"Identification of a 60-kD tumor necrosis factor (TNF) receptor as the major signal transducing component in TNF responses","volume":"172","author":"Thoma","year":"1990","journal-title":"J Exp Med."},{"issue":"2","key":"2021120916264038100_B47","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1084\/jem.181.2.607","article-title":"Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in\u00a0vivo role for p75","volume":"181","author":"Sheehan","year":"1995","journal-title":"J Exp Med."},{"issue":"10","key":"2021120916264038100_B48","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/s41375-018-0207-9","article-title":"Dysregulated iron metabolism in polycythemia vera: etiology and consequences","volume":"32","author":"Ginzburg","year":"2018","journal-title":"Leukemia."},{"issue":"3","key":"2021120916264038100_B49","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.molcel.2020.04.008","article-title":"Single-cell analyses reveal megakaryocyte-biased hematopoiesis in myelofibrosis and identify mutant clone-specific targets","volume":"78","author":"Psaila","year":"2020","journal-title":"Mol Cell."},{"key":"2021120916264038100_B50","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.3389\/fimmu.2020.01660","article-title":"High-dose intravenous immunoglobulins in the treatment of severe acute viral pneumonia: the known mechanisms and clinical effects","volume":"11","author":"Liu","year":"2020","journal-title":"Front Immunol."},{"issue":"4","key":"2021120916264038100_B51","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.seminhematol.2018.04.005","article-title":"Somatic mutations in Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"55","author":"Ferreira Cristina","year":"2018","journal-title":"Semin Hematol."},{"issue":"1","key":"2021120916264038100_B52","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41419-020-2249-y","article-title":"Intravenous immunoglobulin mediates anti-inflammatory effects in peripheral blood mononuclear cells by inducing autophagy","volume":"11","author":"Das","year":"2020","journal-title":"Cell Death Dis."},{"issue":"21","key":"2021120916264038100_B53","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMra1009433","article-title":"Intravenous immune globulin in autoimmune and inflammatory diseases","volume":"367","author":"Gelfand","year":"2012","journal-title":"N Engl J Med."},{"key":"2021120916264038100_B54","first-page":"690","article-title":"Mechanisms of action of Ig preparations: immunomodulatory and anti-inflammatory effects","volume":"5","author":"Matucci","year":"2014","journal-title":"Front Immunol."},{"issue":"2","key":"2021120916264038100_B55","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.clim.2011.08.003","volume":"141","author":"Issekutz","year":"2011","journal-title":"Clin Immunol."},{"issue":"2","key":"2021120916264038100_B56","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/bloodadvances.2018026450","article-title":"Defective negative regulation of Toll-like receptor signaling leads to excessive TNF-\u03b1 in myeloproliferative neoplasm","volume":"3","author":"Lai","year":"2019","journal-title":"Blood Adv."},{"issue":"24","key":"2021120916264038100_B57","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1182\/blood-2013-02-486217","article-title":"Mast cell and macrophage chemokines CXCL1\/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation","volume":"121","author":"Filippode","year":"2013","journal-title":"Blood."},{"issue":"4","key":"2021120916264038100_B58","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1172\/JCI98785","article-title":"Targeting compensatory MEK\/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms","volume":"129","author":"Stivala","year":"2019","journal-title":"J Clin Invest."},{"issue":"3","key":"2021120916264038100_B59","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3390\/ijms19030898","article-title":"Understanding splenomegaly in myelofibrosis: association with molecular pathogenesis","volume":"19","author":"Song","year":"2018","journal-title":"Int J Mol Sci."},{"issue":"2","key":"2021120916264038100_B60","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.exphem.2014.10.013","article-title":"C-X-C motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients","volume":"43","author":"Wang","year":"2015","journal-title":"Exp Hematol."},{"issue":"7","key":"2021120916264038100_B61","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.3324\/haematol.2018.201921","article-title":"SDF1\u03b1DF1l.addaY \u201cx_t\u201d\\\u201c\u201d016\/j.exphem.2014.10.013lopment of extramedullary hemattyrosine k\u03b9\u03bd\u03b1\u03c3\u03b5 \u03b1\u03bd\u03b4 \u03b9\u03c4\u03c3 \u03b4o\u03c9\u03bd\u03c3\u03c4\u03c1\u03b5\u03b1\u03bc \u03c4\u03b1\u03c1\u03b3\u03b5\u03c4\u03c3 \u03a0\u03993\u039a\/\u0391\u039a\u03a4, \u03a0\u039b\u03a7\u03b31 \u03b1\u03bd\u03b4 RhoA","volume":"104","author":"Nimmagadda","year":"2019","journal-title":"Haematologica."},{"issue":"33","key":"2021120916264038100_B62","doi-asserted-by":"crossref","first-page":"54082","DOI":"10.18632\/oncotarget.10789","article-title":"CXCL12\/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner","volume":"8","author":"Abdelouahab","year":"2016","journal-title":"Oncotarget."},{"key":"2021120916264038100_B63","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.2147\/CMAR.S188172","article-title":"Nonspecific immunoglobulin G is effective in preventing and treating cancer in mice","volume":"11","author":"Xu","year":"2019","journal-title":"Cancer Manag Res."},{"issue":"3","key":"2021120916264038100_B64","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/CJI.0b013e31816a88f9","article-title":"A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF) action","volume":"31","author":"Kontermann","year":"2008","journal-title":"J Immunother."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/23\/5349\/1850234\/advancesadv2021004438.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/23\/5349\/1850234\/advancesadv2021004438.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T22:24:41Z","timestamp":1673389481000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/23\/5349\/477104\/Anti-inflammatory-treatment-in-MPN-targeting-TNFR1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,9]]},"references-count":64,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2021,12,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004438","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,9]]}}}